Development of the 21-gene assay and its application in clinical practice and clinical trials

Joseph A. Sparano, Soonmyung Paik

Research output: Contribution to journalArticle

379 Citations (Scopus)

Abstract

Several multigene markers that predict relapse more accurately than classical clinicopathologic features have been developed. The 21-gene assay was developed specifically for patients with estrogen receptor (ER)-positive breast cancer, and has been shown to predict distant recurrence more accurately that classical clinicopathologic features in patients with ER-positive breast cancer and negative axillary nodes treated with adjuvant tamoxifen; validation studies in this population led to its approval as a diagnostic test. In a similar population, it also may be used to assess the benefit of adding chemotherapy to hormonal therapy. Other validation studies indicate that it also predicts the risk of distant and local recurrence in other populations with ER-positive disease, including node-negative patients receiving no adjuvant therapy and patients with positive axillary nodes treated with doxorubicin-containing chemotherapy. The Trial Assigning Individualized Options for Treatment (TAILORx) is multicenter trial that integrates the 21-gene assay into the clinical decision-making process and is designed to refine the utility of the assay in clinical practice and to provide a resource for evaluating additional molecular markers as they are developed in the future.

Original languageEnglish (US)
Pages (from-to)721-728
Number of pages8
JournalJournal of Clinical Oncology
Volume26
Issue number5
DOIs
StatePublished - Feb 2 2008
Externally publishedYes

Fingerprint

Clinical Trials
Estrogen Receptors
Validation Studies
Recurrence
Genes
Breast Neoplasms
Population
Drug Therapy
Tamoxifen
Routine Diagnostic Tests
Doxorubicin
Multicenter Studies
Therapeutics
Clinical Decision-Making

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Development of the 21-gene assay and its application in clinical practice and clinical trials. / Sparano, Joseph A.; Paik, Soonmyung.

In: Journal of Clinical Oncology, Vol. 26, No. 5, 02.02.2008, p. 721-728.

Research output: Contribution to journalArticle

@article{bbf665ff053c48e6a7a3bd905f3a3811,
title = "Development of the 21-gene assay and its application in clinical practice and clinical trials",
abstract = "Several multigene markers that predict relapse more accurately than classical clinicopathologic features have been developed. The 21-gene assay was developed specifically for patients with estrogen receptor (ER)-positive breast cancer, and has been shown to predict distant recurrence more accurately that classical clinicopathologic features in patients with ER-positive breast cancer and negative axillary nodes treated with adjuvant tamoxifen; validation studies in this population led to its approval as a diagnostic test. In a similar population, it also may be used to assess the benefit of adding chemotherapy to hormonal therapy. Other validation studies indicate that it also predicts the risk of distant and local recurrence in other populations with ER-positive disease, including node-negative patients receiving no adjuvant therapy and patients with positive axillary nodes treated with doxorubicin-containing chemotherapy. The Trial Assigning Individualized Options for Treatment (TAILORx) is multicenter trial that integrates the 21-gene assay into the clinical decision-making process and is designed to refine the utility of the assay in clinical practice and to provide a resource for evaluating additional molecular markers as they are developed in the future.",
author = "Sparano, {Joseph A.} and Soonmyung Paik",
year = "2008",
month = "2",
day = "2",
doi = "10.1200/JCO.2007.15.1068",
language = "English (US)",
volume = "26",
pages = "721--728",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Development of the 21-gene assay and its application in clinical practice and clinical trials

AU - Sparano, Joseph A.

AU - Paik, Soonmyung

PY - 2008/2/2

Y1 - 2008/2/2

N2 - Several multigene markers that predict relapse more accurately than classical clinicopathologic features have been developed. The 21-gene assay was developed specifically for patients with estrogen receptor (ER)-positive breast cancer, and has been shown to predict distant recurrence more accurately that classical clinicopathologic features in patients with ER-positive breast cancer and negative axillary nodes treated with adjuvant tamoxifen; validation studies in this population led to its approval as a diagnostic test. In a similar population, it also may be used to assess the benefit of adding chemotherapy to hormonal therapy. Other validation studies indicate that it also predicts the risk of distant and local recurrence in other populations with ER-positive disease, including node-negative patients receiving no adjuvant therapy and patients with positive axillary nodes treated with doxorubicin-containing chemotherapy. The Trial Assigning Individualized Options for Treatment (TAILORx) is multicenter trial that integrates the 21-gene assay into the clinical decision-making process and is designed to refine the utility of the assay in clinical practice and to provide a resource for evaluating additional molecular markers as they are developed in the future.

AB - Several multigene markers that predict relapse more accurately than classical clinicopathologic features have been developed. The 21-gene assay was developed specifically for patients with estrogen receptor (ER)-positive breast cancer, and has been shown to predict distant recurrence more accurately that classical clinicopathologic features in patients with ER-positive breast cancer and negative axillary nodes treated with adjuvant tamoxifen; validation studies in this population led to its approval as a diagnostic test. In a similar population, it also may be used to assess the benefit of adding chemotherapy to hormonal therapy. Other validation studies indicate that it also predicts the risk of distant and local recurrence in other populations with ER-positive disease, including node-negative patients receiving no adjuvant therapy and patients with positive axillary nodes treated with doxorubicin-containing chemotherapy. The Trial Assigning Individualized Options for Treatment (TAILORx) is multicenter trial that integrates the 21-gene assay into the clinical decision-making process and is designed to refine the utility of the assay in clinical practice and to provide a resource for evaluating additional molecular markers as they are developed in the future.

UR - http://www.scopus.com/inward/record.url?scp=39149113165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149113165&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.15.1068

DO - 10.1200/JCO.2007.15.1068

M3 - Article

C2 - 18258979

AN - SCOPUS:39149113165

VL - 26

SP - 721

EP - 728

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -